MorphoSys and Roche Expand Therapeutic Antibody Partnership

MorphoSys AG and Roche have announced a collaboration to develop therapeutic antibodies in oncology.

Expanding on a September 2000 relationship in Alzheimer's disease, Roche will elect target molecules against which MorphoSys will generate antibodies using its proprietary HuCAL GOLD® technology.

"Extending our active alliance shows a positive and constructive working relationship between Roche and MorphoSys," said Peter Hug, Roche's Global Head of Pharma Partnering. "We are pleased to collaborate with a proven partner in a new therapeutic area."

"Roche's commitment to initiating new therapeutic antibody programs with MorphoSys is a clear vote of confidence from an existing partner and validation of the utility of our technology in producing potential drugs."

Under the terms of the agreement, Roche and MorphoSys will collaborate on two new antibody programs in oncology.

Roche will be responsible for preclinical and clinical development as well as subsequent marketing of all resulting products.

MorphoSys will receive an upfront payment and may receive additional research funding and future event payments totaling more than EUR 10 million per program, plus potential royalties.

RELATED ARTICLES

Calidi Biotherapeutics, Inc., formerly StemImmune, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, announced a focused effort to advance its oncolytic virus drug development.

How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.